Liquidia patent ruling upholds YUTREPIA infringement, putting PH-ILD access at risk

Liquidia is no longer an early-stage biotech story: YUTREPIA launched commercially in June 2025, generated $170.4 million of second-quarter 2026 product sales, and has become the company’s main operating engine, while L606 remains an investigational follow-on program. This ruling hits the company’s core commercial product, not a peripheral pipeline asset. The Court found claims 1 and 14 of United Therapeutics’ ’327 patent valid and infringed by Liquidia, even though the other asserted claims were invalid.

The immediate business risk is loss of part of YUTREPIA’s approved market, with a wider restriction still possible. Liquidia says the remedy could range from removing the PH-ILD indication from the label to restricting YUTREPIA’s availability more broadly, and United Therapeutics is seeking injunctive relief that would limit sales. 〔0〕 That is materially worse than the pre-ruling position, when Liquidia could market YUTREPIA for both PAH and PH-ILD while the case remained unresolved.

Liquidia has a mitigation path, but it is not an outcome. Management says it intends to submit an FDA supplement removing PH-ILD from the label and will pursue appeals. 〔1〕 That could preserve the PAH business if accepted and if the Court does not impose a broader injunction, but the filing provides no assurance on either point. Liquidia also explicitly says it cannot yet estimate the financial exposure. 〔2〕

The result is partly known in direction but newly adverse in legal certainty. The litigation, the possibility of an injunction, and the PH-ILD-label strategy were already disclosed risks; the new information is that the Court has now entered an infringement finding on two claims and is moving directly to remedies. The company has one week to submit a proposed form of judgment, after which the scope of any restriction should become clearer.

Bottom line: The ruling does not automatically shut down YUTREPIA, but it converts a major legal overhang into an immediate threat to the product’s approved label and potentially its market access. That is a meaningful setback to Liquidia’s central commercial story, with the final damage hinging on the remedy and appeals process.